Gestational diabetes mellitus (GDM) is a common complication of pregnancy in which women without previously diagnosed diabetes develop chronic hyperglycemia during pregnancy. It is associated with a number of maternal and fetal/neonatal complications. The role of the adipokines retinol binding protein-4, resistin and nesfatin-1 in the development of GDM is relatively poorly understood, but their role in glucose metabolism is suspected and their use as early markers to predict the development of GDM is being sought. The aim of study was to determine the correlation between the levels of selected adipokines (retinol binding protein-4, resistin, nesfatin-1) in women with gestational diabetes mellitus (GDM) and healthy pregnant women and to compare their levels with other clinical and biochemical parameters. Patients with GDM had significantly higher BMI (28.4±4.5 vs. 24.6±4 kg/m2), total cholesterol (6±1.3 vs. 5.3±1.4 mmol/l) and triacylglycerols (1.9±0.8 vs. 1.4±0.7 mmol/l) than women in the control group. RBP4 confirms the significant difference between the groups, it is higher in the control group of healthy pregnant women. The adipokines resistin and nesfatin-1 show no differences between the control and GDM groups, but their ratios with BMI, cholesterol and triacylglycerols, resistin shows elevated levels in the control group. In women with GDM, RBP4 was significantly positively correlated with C-peptide and negatively correlated with total, LDL, and non-HDL cholesterol. Resistin was also negatively correlated with total, LDL, HDL, and non-HDL cholesterol. Nesfatin-1 was only moderately positively correlated with glycated hemoglobin (HbA1C) and fasting glycemia. There is ambiguity in the results of previous studies on the levels of the investigated adipokines in pregnant women with GDM and the interpretation depends on many factors. Keywords: Gestational diabetes, Adipokines, Retinol-binding protein 4, Resistin, Nesfatin-1.
- MeSH
- Adipokines blood MeSH
- Biomarkers * blood MeSH
- DNA-Binding Proteins blood MeSH
- Adult MeSH
- Diabetes, Gestational * blood diagnosis MeSH
- Blood Glucose metabolism MeSH
- Humans MeSH
- Nucleobindins * blood MeSH
- Retinol-Binding Proteins, Plasma * metabolism analysis MeSH
- Nerve Tissue Proteins blood MeSH
- Calcium-Binding Proteins blood MeSH
- Resistin * blood MeSH
- Case-Control Studies MeSH
- Pregnancy MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
Cíl studie: Práce je zaměřena na evaluaci akce Movember 2022 ve Fakultní nemocnici Olomouc, jejíž cílem bylo nabídnout zájemcům z řad mužů vyšetření hladiny prostatického specifického antigenu (PSA) v séru. U jedinců s abnormálními hladinami byl následně sledován vývoj diagnózy. Zjištěné výsledky byly vyhodnoceny ve vztahu k aktuálnímu programu screeningu rakoviny prostaty v České republice. Typ studie: Observační studie. Materiál a metody: V séru subjektů byly vyšetřeny celkové a freePSA pomocí chemiluminiscenční imunoanalýzy. Výsledky: Akce Movember 2022 se zúčastnilo celkem 348 mužů. Výsledky byly vyhodnoceny v závislosti na věku probandů. Skupině vyšetřených s hodnotou PSA 2 - 10 μg/L byla stanovena hodnota freePSA a vypočítán procentuální poměr freePSA/PSA. Celkem byli zachyceni čtyři pacienti, u nichž byla následně potvrzena diagnóza zhoubného novotvaru prostaty. Tyto případy jsou prezentovány formou kazuistik. Výsledky jsou diskutovány vzhledem k pilotnímu screeningovému programu Ministerstva zdravotnictví ČR (MZČR) pro časný záchyt karcinomu prostaty. Závěr: Metodika MZČR nastavuje poměrně jasné algoritmy, které vycházejí z klinických zkušeností, studií a dat. Vyhodnocení přínosu zavedeného screeningu je nutné vyhodnotit v rámci dlouhodobého horizontu. Individuální perspektiva dožití, zdravotní stav, přidružené komorbidity a věk, by měly být ústředním bodem klinických rozhodnutí o screeningu, diagnostice a léčbě karcinomu prostaty.
Objective: The work is focused on evaluating the Movember 2022 event at the University Hospital in Olomouc, the aim of which was to offer men interested in prostate-specific antigen (PSA) serum testing. Individuals with abnormal levels were subsequently followed up for diagnosis. The findings were evaluated in relation to the current prostate cancer screening programme in the Czech Republic. Design: Observational studies. Material and Methods: The serum of the subjects was examined for total and freePSA by chemiluminescence immunoassay. Results: A total of 348 men participated in Movember 2022. The results were evaluated according to the age of the probands. For the group of subjects with a PSA level of 2 - 10 μg/L, the freePSA value was determined, and the percentage of freePSA/PSA was calculated. A total of 4 patients were captured and subsequently diagnosed with malignant neoplasm of the prostate. These cases are presented as case reports. The results are discussed in relation to the pilot screening program of the Ministry of Health of the Czech Republic (MZCR) for early detection of prostate cancer. Conclusion: The MZCR methodology sets relatively clear algorithms based on clinical experience, studies and data. The evaluation of the benefits of established screening needs to be evaluated in the long term. Individual survival perspective, health status, associated comorbidities, and age should be central to clinical decisions on screening, diagnosis and reatment of prostate cancer.
- MeSH
- Hepatitis B epidemiology MeSH
- Hepatitis C epidemiology MeSH
- HIV Infections epidemiology MeSH
- Incidence MeSH
- Humans MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Abstracts MeSH
- Geographicals
- Czech Republic MeSH
- MeSH
- Chronic Disease MeSH
- Hepacivirus immunology MeSH
- Hepatitis B epidemiology immunology MeSH
- Hepatitis C Antibodies analysis MeSH
- Hepatitis C epidemiology immunology MeSH
- Liver Cirrhosis epidemiology immunology MeSH
- Middle Aged MeSH
- Humans MeSH
- Prevalence MeSH
- Seroepidemiologic Studies MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Publication type
- Letter MeSH
- Geographicals
- Czech Republic MeSH
